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http:WHAT THIS STUDY ADDS
Currently, the majority of patients with peripheral arterial disease are unable to access supervised exercise
programmes because of a lack of funding. This study demonstrates that these programmes are cost-effective by
international standards, leading to an increased length and quality of life at a reasonable cost. The results of this
research were used to inform recommendations for reimbursement of supervised exercise programmes in the
UK.Background: Supervised exercise (SE) is thought to result in improvements in walking distance and quality of life
compared with unsupervised exercise (USE) in people with intermittent claudication. However, the cost-
effectiveness of SE is unclear. As a result, many patients are currently unable to access supervised programmes.
Methods: We searched MEDLINE, Embase, Cochrane, and Cinahl databases to identify randomised controlled
trials comparing USE with SE in adults with intermittent claudication. A Markov model was developed to estimate
costs and quality adjusted life years (QALYs) from an NHS and personal social services perspective. Quality of life
was obtained from the included clinical trials. Resource use was modelled on current programmes and unit costs
were based on published sources.
Results: Depending on estimated rates of compliance, SE was cost-effective in over 75% of model simulations,
with an incremental cost-effectiveness ratio of £711 to £1,608 per QALY gained. The model was sensitive to long-
term effects of exercise on cardiovascular risk and quality of life.
Conclusions: SE is more cost-effective than USE for the treatment of people with intermittent claudication.
Supervised programmes should be made widely available and offered as a ﬁrst line treatment to people with
intermittent claudication.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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analysisINTRODUCTION
Intermittent claudication (IC) is the most common symptom
of peripheral arterial disease (PAD) and is characterised by
discomfort in the legs that is brought on by walking
and relieved by rest. People with IC often have limited
functional status and are at increased risk of cardiovascular
(CV) morbidity and mortality.1 People often adapt byrresponding author. S.L. Bermingham, Royal College of Physicians,
al Clinical Guideline Centre, 11 St Andrews Place, London NW1 4LE,
il address: s.l.bermingham@gmail.com (S.L. Bermingham).
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//dx.doi.org/10.1016/j.ejvs.2013.09.005decreasing their level of physical activity, but evidence
suggests regular exercise improves walking ability.
People with IC may be offered unsupervised exercise
(USE) or supervised exercise (SE) programmes. Two
Cochrane reviews have found that SE leads to a greater
improvement in walking distance when compared with
USE.2,3 However, whether SE results in a clinically mean-
ingful increase in quality of life (QoL) or is cost-effective is
unclear. To date, two cost-utility analyses have compared SE
and USE for the treatment of IC.4,5 However, these studies
either used ﬂawed methods of measurement4 or did not
account for the beneﬁcial effects of exercise on CV health.5
The aim of this study was to determine which type of
exercise represents the most cost-effective treatment
strategy for people with IC. The results of this research were
Figure 1. Schematic Markov model structure. The costs and con-
sequences of IC were modelled as movements between ﬁve health
states of a Markov transition model. People entered the model in
an “active state”, which was used to describe people who main-
tained a similar level of activity to that reported in the clinical
trials; this level of activity closely matches the deﬁnition of an
“active” lifestyle used by other sources of data included in the
model, including the 2006 Health Survey for England (30 minutes
or more of moderate to vigorous activity 1 to 4 days per week).
When individuals failed to comply with the recommended level of
exercise, they became “inactive”. For simplicity, people who
experienced a non-fatal cardiovascular event (deﬁned as non-fatal
stroke or MI) entered a health state from which the only available
transition was death. Circular arrows indicate residual probabilities
(i.e. one minus the sum of all other transition probabilities from
that health state).
708 S.L. Bermingham et al.used to inform recommendations within the 2012 NICE
guideline Lower limb peripheral arterial disease: Diagnosis
and management.6
METHODS
We searched MEDLINE (OVID), Embase (OVID), the
Cochrane Library, and Cinahl (EBSCO) from their date of
inception to 9 January 2012 to identify randomised
controlled trials (RCTs) comparing USE with SE in adults
(18 years) with IC (see Supplementary Files). We then
conducted a cost-utility analysis comparing SE with USE for
the treatment of IC. The analysis was undertaken from a UK
NHS and personal social services perspective. Results were
expressed in terms of costs, quality adjusted life years
(QALYs), and incremental cost per QALY gained. All costs
were reported in 2009/10 UK pounds. Both costs and QALYs
were discounted at an annual rate of 3.5%.7
Population and comparators
We considered a hypothetical population of people with IC
who were suitable for and willing to exercise. Based on the
systematic review, this cohort had a mean starting age of 67
years, average ankle brachial pressure index (ABPI) of 0.67,
and 66% were male.6 Twenty-four per cent of people had
diabetes; 43% were current smokers.6 Not included were
people with co-morbidities preventing participation in an
exercise programme, those who had recently undergone
endovascular intervention, or who had critical limb
ischaemia (CLI). As reported by included RCTs, all were
receiving best medical therapy at baseline (comprising
smoking cessation advice; antiplatelet, anti-hypertensive,
and cholesterol-lowering therapy; and control of diabetes).
USE was deﬁned as advice to exercise for approximately
30 minutes three to ﬁve times per week, walking until the
point of maximal pain, then resting to recover. Studies in
which USE consisted of a lifestyle or educational pro-
gramme (in addition to advice to exercise) were excluded as
it would not be possible to isolate the treatment effect
caused by the exercise component of the programme from
that of the lifestyle advice/education. SE was deﬁned as a
community-, hospital-, or gym-based programme super-
vised by healthcare professionals. SE programmes are
typically supervised by two physiotherapists and have
approximately 10 patients per group. The programme con-
sists of approximately 2 hours of classes per week for 3
months. People are asked to exercise to the point of
maximal pain, then allowed to rest; they may walk on
treadmills or on the ﬂat, inside or outside, or may complete
circuits of different exercises. The model did not evaluate
different durations, intensities or modes of exercise within
SE programmes.
Approach to modelling and baseline transition
probabilities
The primary treatment goals for people with IC are to
improve walking distance and QoL. Treatment should also
aim to reduce overall CV risk and mortality. Participation inregular physical activity is associated with an improvement
in each of these outcomes. However, improvements in CV
function rapidly deteriorate with inactivity or a reduction in
exercise training,8 and the QoL gain reported by people
who have completed an exercise programme is only
maintained if people continue to be active.9 Therefore, a
key assumption of the model was that compliance to the
recommended level of physical activity was needed to
provide the beneﬁts associated with the programme.
People who reverted to a relatively inactive state were
assumed to also revert to baseline QoL, mortality, and CV
risk.
Fig. 1 illustrates the key health states in our model and
the possible transitions between them during each cycle.
We used a cycle length of 3 months to correspond with
follow-up intervals reported by studies included in the
systematic review. Age- and sex-speciﬁc all-cause mortality
rates were based on the most recent available life tables for
the general population,10 multiplied by the standardised
risk of all-cause mortality observed over 10 years in people
with IC.11 The model was run over the lifetime of the
cohort.
Average baseline risk of myocardial infarction (MI) and
stroke by age and sex was calculated using Framingham risk
equations and a spreadsheet developed by Payne 2010,12,13
with risk factor inputs derived from the Health Survey for
England 200614 and the NICE hypertension model.15 A
recent study by the Ankle Brachial Index Collaboration was
Table 1. Baseline transition probabilities, utilities and costs.
Parameter Mean 95% conﬁdence interval Source
Baseline relative risk for people with IC compared with adjusted norms
All cause mortality 3.10 1.90e4.90 Criqui et al.11
Stroke & MI Male 2.16 1.76e2.66 Ankle Brachial Index Collaboration1
Female 2.49 1.87e3.36 Ankle Brachial Index Collaboration1
Relative risk for active compared with inactive individuals
All cause mortality 0.87 0.75e0.99 Heran et al.17
MI 0.97 0.82e1.15 Heran et al.17
Stroke 0.80 0.74e0.86 Lee et al.18
Unsupervised exercise utilities
USE Baseline 0.636 0.602e0.668 Cheetham et al.22 van Asselt et al.5 and Savage et
al.20,21
USE 3 months 0.692 0.658e0.725 Cheetham et al.22 van Asselt et al.5 and Savage et
al.21
USE 6 months 0.692 0.664e0.720 Cheetham et al.22 van Asselt et al.5 and Savage et
al.21
USE 9 months 0.692 0.654e0.727 Cheetham et al 2004,22 van Asselt et al 2011,5
and Savage et al.21
USE 12 months 0.671 0.625e0.714 Cheetham et al.22 van Asselt et al.5 and Savage et
al.21
Supervised exercise utilities
SE Baseline 0.672 0.643e0.700 Cheetham et al.22 van Asselt et al.5 and Savage et
al.21
SE 3 months 0.709 0.649e0.738 Cheetham et al.22 van Asselt et al.5 and Savage et
al.21
SE 6 months 0.732 0.707e0.756 Cheetham et al.22 van Asselt et al 2011,5 and
Savage et al.21
SE 9 months 0.744 0.711e0.775 Cheetham et al.,22 van Asselt et al.5 and Savage
et al.21
SE 12 months 0.748 0.714e0.780 Cheetham et al.22 van Asselt et al.5 and Savage et
al.21
Cardiovascular event utilities
MI 0.497 0.469e0.525 Lovibond et al.15
Stroke 0.576 0.554e0.598 Lovibond et al.15
Post MI 0.412 0.192e0.297 Lovibond et al.15
Post stroke 0.533 0.502e0.564 Lovibond et al.15
Costs
Supervised exercise £288 £232 to £345 See Table 3
Unsupervised exercise £0 NA Expert opinion
MI £4 792 £3 853 to £5 731 Lovibond et al.15
Post MI £141 £113 to £169 Lovibond et al.15
Stroke £9 630 £7 743 to £11 517 Lovibond et al.15
Post stroke £559 £449 to £669 Lovibond et al.15
IC ¼ intermittent claudication; MI ¼ myocardial infarction
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people with an ABPI of between 0.61 and 0.70.1 Baseline
transition probabilities are reported in Table 1.
The RCTs included in the systematic review6 did not
report CV events or mortality, nor did a wider search of the
literature reveal any RCTs investigating the relationship
between exercise and either of these outcomes in people
with PAD. Given that the risk of CV morbidity and mortality
in people with PAD is comparable with the risk faced by
people with established CV disease,16 we used the results of
a recent Cochrane review17 of the effect of exercise-based
rehabilitation in people with coronary heart disease to
inform the risk of total mortality and MI following an
exercise-based cardiac rehabilitation programme comparedwith non-active controls. The risk of stroke for active
compared with inactive people was obtained from a recent
meta-analysis.18Quality of life
Seven of the studies included in the systematic review re-
ported QoL using a generic measure such as the Short Form
(SF) questionnaires, EuroQol (EQ-5D), or Health Utilities
Index. EQ-5D values collected as part of the EXITPAD
study19 were reported by van Asselt et al.5 Five papers,
representing an additional four trials, reported SF-36
outcomes: two20,21 published full results for each domain
at each time point included in the study; one reported
710 S.L. Bermingham et al.results graphically;22 one reported results only for statistically
signiﬁcant domains;23 and one did not report results for all time
points.19 The authors of these studieswere contacted to request
additional data. Pinto et al.23 were unable to provide further
information. Nicolai et al.19 and Cheetham et al.22 provided
mean SF-36 scores and permission to include these data in the
current analysis. One study reported outcomes from the SF-20.24
Because validated mapping algorithms are not available for this
questionnaire, additional data were not requested.
The EQ-5D is the preferred measure of QoL in cost-utility
analyses. To estimate EQ-5D values using mean SF-36 sta-
tistics, each dimension score was assigned a gamma dis-
tribution according to the method of moments.25 A random
number generator was used to produce probabilistic
dimension scores, which were incorporated into the algo-
rithm described by Ara and Brazier.26 This calculation was
repeated 20,000 times using Monte Carlo simulation to
calculate mean mapped EQ-5D values (Table 2).
Change in QoL between 3-month follow-up intervals and
the difference in this change between interventions (i.e.
mean difference in change) were calculated for each trial by
the same method. A weighted average baseline utility of
0.654 (95% CI 0.633 to 0.676) was then calculated according
to the number of people in each trial. Weighted mean dif-
ferences in change were applied to the baseline utility toTable 2. Reported EQ-5D, SF 36, and mapped EQ-5D values.a
Unsupervised exercise
Baseline 3 months 6 months 9 months 12 month
Mean (SD) EQ-5D values reported by the EXITPAD study (van Asse
EQ-5D 0.62 (0.23) 0.68 (0.23) 0.69 (0.19) 0.68 (0.23) 0.66 (0.26
SF-36
Median (IQR) SF-36 scores from Cheetham 200422 c
PF 50 (20) 55 (NR) 55 (NR) 55 (NR) 55 (NR)
RP 56 (19) 53 (NR) 56 (NR) 56 (NR) 56 (NR)
BP 70 (36) 71 (NR) 70 (NR) 77 (NR) 71 (NR)
GH 59 (27) 56 (NR) 59 (NR) 63 (NR) 59 (NR)
V 53 (12) 53 (NR) 59 (NR) 56 (NR) 53 (NR)
SF 81 (37) 81 (NR) 81 (NR) 81 (NR) 81 (NR)
RE 67 (42) 71 (NR) 75 (NR) 67 (NR) 67 (NR)
MH 70 (40) 70 (NR) 70 (NR) 73 (NR) 70 (NR)
EQ-5D 0.65 (0.02) 0.71 (0.02) 0.70 (0.02) 0.73 (0.02) 0.71 (0.02
Mean (SD) SF-36 scores reported by Savage 200121 d
PF 45 (17) 61 (10) 54 (27) NR NR
RP 47 (47) 68 (43) 47 (46) NR NR
BP 50 (13) 72 (23) 64 (14) NR NR
GH 67 (9) 65 (17) 65 (19) NR NR
V 49 (22) 47 (6) 52 (19) NR NR
SF 85 (19) 90 (15) 85 (20) NR NR
RE 75 (46) 81 (38) 74 (43) NR NR
MH 83 (13) 74 (17) 65 (31) NR NR
EQ-5D 0.66 (0.03)* 0.76 (0.03)* 0.68 (0.04)* NA NA
Abbreviations: PF ¼ physical function; RP ¼ role physical; BP ¼ bodily
RE ¼ role emotional; MH ¼ mental health; SD ¼ standard deviation; IQ
a SF-36 scores reported by Kakkos 200520 could not be mapped to EQ
Asselt 20115 reported different quality of life outcomes from the same
by van Asselt 2011 were used in preference to SF-36 scores reported
b Data reported in published paper.
c Data provided by author with permission.
d Mapped based on algorithm (Equation 1) reported by Ara and Braziestimate incremental utility gain associated with SE at each
cycle (see Supplementary Files).
QoL gains associated with SE were maintained for people
who continued to exercise. Those who stopped exercising
were assigned baseline utility. The effect of using values from
each individual trial was explored in sensitivity analysis, as
was the impact of assuming a greater cost of SE to reﬂect a
longer average trial duration. QoL associated with CV events
was derived by Lovibond and colleagues (Table 1).15Costs
The cost of SE was based on estimates of resource use
informed by expert opinion and published unit costs27
(Table 3). Because the cost of the initial GP consultation is
common to both USE and SE, it was not included in the cost of
either. The cost of USE was assumed to be £0.This was varied
in sensitivity analysis to account for different levels of support
that could be provided by different types of USE.
The approach to modelling CV events was based on a
publishedmodel for ambulatory blood pressuremonitoring.15
CV events were assigned an initial cost representing the acute
managementand/ordiagnosis in theﬁrst cycle and anongoing
cost representing the average3-month cost following anevent
in each subsequent cycle (Table 1).Supervised exercise
s Baseline 3 months 6 months 9 months 12 months
lt 2011)5 b
) 0.66 (0.20) 0.69 (0.21) 0.72 (0.17) 0.73 (0.21) 0.74 (0.20)
60 (20) 65 (NR) 70 (NR) 70 (NR) 70 (NR)
75 (44) 75 (NR) 84 (NR) 81 (NR) 88 (NR)
59 (29) 72 (NR) 71 (NR) 72 (NR) 72 (NR)
67 (22) 65 (NR) 67 (NR) 70 (NR) 62 (NR)
56 (37) 56 (NR) 62 (NR) 65 (NR) 62 (NR)
88 (50) 88 (NR) 88 (NR) 88 (NR) 88 (NR)
67 (50) 67 (NR) 67 (NR) 67 (NR) 67 (NR)
75 (35) 75 (NR) 80 (NR) 80 (NR) 75 (NR)
) 0.71 (0.02) 0.76 (0.02) 0.79 (0.02) 0.79 (0.02) 0.78 (0.02)
54 (14) 60 (16) 56 (14) NR NR
84 (30) 77 (34) 84 (19) NR NR
59 (20) 70 (18) 65 (19) NR NR
71 (17) 64 (14) 66 (18) NR NR
66 (17) 68 (17) 63 (16) NR NR
91 (11) 92 (10) 91 (10) NR NR
97 (10) 82 (35) 71 (45) NR NR
79 (16) 82 (12) 73 (17) NR NR
0.68 (0.03)* 0.74 (0.03)* 0.69 (0.03)* NA NA
pain; GH ¼ general health; V ¼ vitality; SF ¼ social functioning;
R ¼ interquartile range; NA ¼ not applicable; NR ¼ not reported.
-5D scores based on median values of 0. Nicolai 201019 and van
study (EXITPAD). In the base case analysis, EQ-5D values reported
by Nicolai 2010. See Supplementary Files for more information.
er 2008.26
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Assessing the value of an intervention requires an under-
standing of its impact in real-world settings. Although ﬁve
RCTs included in the systematic review reported withdrawal
rates (see Supplementary Files), we considered compliance
within interventional studies to represent behaviour in a
limited population within a controlled environment and
therefore to be unsuitable for decision modelling. The
literature was reviewed for observational, retrospective, or
administrative estimates of short- and long-term compli-
ance to USE and SE in people with PAD, CV disease, or older
adults in the community. The aim of this review was to
estimate the percentage of people who would complete the
initial 3 months of each exercise programme, as well as the
proportion that would remain active over time. No relevant
evidence was identiﬁed. In the absence of applicable data, a
group of patients and healthcare professionals familiar with
these programmes were asked to provide expert opinion by
way of an online survey (see Appendix K of the full guideline
for more information, http://guidance.nice.org.uk/CG147/
Guidance).
Seventeen people (six physiotherapists, ﬁve vascular
surgeons, ﬁve vascular nurses, and one patient represen-
tative) completed the survey. On average, respondents
estimated that SE leads to greater compliance over both the
short (6 months) and long term (6e24 months). However,
there was much more uncertainty over long-term compli-
ance than with short-term. To reﬂect this uncertainty, two
scenarios were developed. In each scenario, SE was
assumed to lead to greater compliance over the short term.
Over the longer term, compliance to SE was assumed to be
greater than USE in Scenario 1 and equal to USE in Scenario
2 (Fig. 2).Table 3. Cost of a 3-month supervised exercise programme.
Programme duration and intensity
2 hours of class per week for 3 months (13 weeks)a
Ten people per classb
Resource use Unit cost
Two physiotherapistsb £37 (2) per hourc
One physiotherapist technicianb £22 per hourc
Room hire and equipment rentalb £15 per hourb
Associated cost of supervised exercise programme
Total programme cost
(per 10-person group)
£2,886
Total programme cost per
patient (range)
£288 (£232 to £345)d
a Average length and duration of exercise programmes evaluated
by RCTs included in systematic review (see Supplementary Files).
b Based on expert opinion: several guideline development group
members sent requests for information to their clinical colleagues
and commissioning managers and responses were received from
around the country. A number of different models were described
and discussed by the group. The resource use described in the
Table was thought to represent the typical pattern for outpatient
care of people with IC.
c Obtained from the 2010 Personal Social Services Research Unit.27
d A standard error of 10% resulted in a range that was thought to
be reasonably representative of the variation in the cost of
different supervised exercise programmes across the country.Uncertainty
The model was developed probabilistically and assessed by
Monte Carlo simulation.28 A probability distribution was
deﬁned for each parameter based on reported point esti-
mates and standard errors. The model was run 20,000
times. This number was chosen to ensure that Monte Carlo
error was below 5% of the standard error for both the in-
cremental cost and incremental QALYs of each parameter
compared with the baseline. Each time the model was run,
values for each input parameter were randomly selected
from their respective distributions. Mean costs and QALYs
were calculated by averaging across all 20,000 simulations.
Two scenarios are presented as part of the base case
analysis. For each scenario, one- and two-way sensitivity
analyses surrounding data and assumptions related to QoL,
CV events, mortality, and cost were undertaken to test the
robustness of the model.
RESULTS
The results of the cost-effectiveness analysis indicate that
under both scenarios, SE is more effective and more costly
than USE. Assuming that SE leads to greater compliance
over both the short and long term, it costs £191 more and
results in an average gain of 0.268 QALYs per patient
compared with USE. This yields an ICER of £711 per QALY
gained. If we assume that there is no difference in
compliance between USE and SE beyond 1 year, SE is £215
more costly and results in an average of 0.134 more QALYs
compared with USE, yielding an ICER of £1,608 per QALY
gained. At a threshold of £20,000, SE was more cost-
effective than USE in 79% and 75% of model iterations,
respectively (Table 4).
Sensitivity analyses
A wide range of probabilistic sensitivity analyses showed
that SE is the most cost-effective strategy for the majority of
values and assumptions tested (Table 5). The exception to
this was if all key assumptions about the beneﬁts of exercise
were removed from the model. If we do not extrapolate
QoL beyond the trial end dates and do not attribute a
beneﬁt in terms of CV morbidity or mortality in people who
are active, SE is unlikely to be cost-effective. In addition,
when both cost and compliance to USE is increased, SE is
unlikely to be cost-effective (see Appendix K of the full
guideline for more information, http://guidance.nice.org.
uk/CG147/Guidance).
DISCUSSION
Our results show that SE is more cost-effective than USE in
over 75% of model simulations. At a cost of £711 to £1,608
per QALY gained, SE would be considered highly cost-
effective by policy makers worldwide.29 Currently, the ma-
jority of Europeans with IC do not have access to SE.30 Our
research shows that once established, SE programmes are
highly likely to represent good value for money.
Implementation of these programmes will require
substantial investment. This is likely to pose a challenge,
Figure 2. Compliance with supervised and unsupervised exercise: two alternative model scenarios. L ¼ average lowest estimate;
ML ¼ average most likely estimate; H ¼ average highest estimate. The average results of the survey were used to inform the absolute
probabilities used in Scenario 1. For Scenario 2, the average results were used to inform the estimate for unsupervised exercise and the
values for supervised exercise were adjusted accordingly.
712 S.L. Bermingham et al.particularly in Europe, where expenditures in most coun-
tries are divided across several budgets and there is a
tendency to consider each in isolation.29 An intervention
like SE is likely to have an impact across many budgets. For
example, programme costs may be incurred in primary or
public healthcare settings, whereas savings realised by
fewer CV events are likely to be distributed across primary,
secondary, and tertiary settings. To be useful as a tool for
demonstrating value, decision makers must consider the full
impact of an intervention across the healthcare system.
Although robust to a wide range of sensitivity analyses,
the results were sensitive to key assumptions about long-
term QoL, CV beneﬁt, and compliance. If exercise does
not lead to a sustained increase in QoL, or a decrease in CV
risk in those who continue to be active, SE is unlikely to be
more cost-effective than USE. Similarly, if SE leads to poorer
compliance than USE it does not represent the optimal
strategy. Overall, we thought these outcomes to be very
unlikely.
The methods used to develop the model are subject to
several limitations. Firstly, the data used to estimate the risk
of mortality and CV events for active individuals was
derived from studies conducted in people with MI and
other CV diseases. This population may have a differentTable 4. Mean probabilistic results of the cost-effectiveness model.
Strategy Total cost Incremental cost Total QALYs Incremental
Scenario 1 e Greater long term compliance to supervised exercise
Unsupervised £2, 499 Baseline 5.082 Baseline
Supervised £2, 690 £191 5.350 0.268
Scenario 2 e Equal long term compliance
Unsupervised £2, 499 Baseline 5.078 Baseline
Supervised £2, 714 £215 5.212 0.134
QALY ¼ quality adjusted life year; CE ¼ cost-effective.
a At a threshold of £20, 00 per QALY gained.exercise capacity compared with people with IC and this
may affect the magnitude of the effect size.31 In addition,
many of the trials included in the Cochrane review predate
what is considered current “best medical therapy”; the
introduction of statins, for example, may have an effect on
observed outcomes (however, this limitation would equally
apply to all studies conducted in people with PAD). Sec-
ondly, the number of respondents to the survey used to
estimate compliance to SE and USE was small and the
majority were physicians, who have been reported to over-
estimate patient compliance to exercise.32,33 The survey
was edited by the guideline development group prior to
distribution but was not validated in a systematic way.
Thirdly, the systematic review was not designed to distin-
guish between RCTs of varying length, duration, or intensity
of SE. Therefore, we were not able to determine whether
certain types of SE are more cost-effective than others.
Lastly, limited published data were available to inform the
impact of exercise programmes on QoL beyond 1 year.
Two previous studies have been designed to address this
question.4,5 Unfortunately, one used the SF-36 index score
as a measure of utility without accounting for preference
weighting.4 The other was limited by a 1-year time horizon
and failed to explicitly capture differences in complianceQALYs Incremental cost per QALY Probability of being CE (%)a
Baseline 21
£711 79
Baseline 25
£1, 608 75
Table 5. Sensitivity analyses (probabilistic).
Compliance scenario 1 Compliance scenario 2
D Costs D QALY ICER Probability
SE is CEa
D Costs D QALY ICER Probability
SE is CEa
Baseline risk of mortality
Baseline relative risk of mortality set to 4.41 £199 0.231 £858 79 £216 0.114 £1903 74
Baseline relative risk of mortality set to 1.42 £168 0.334 £502 79 £212 0.166 £1,275 75
Key model assumptions
No mortality beneﬁt from exercise £175 0.214 £818 76 £213 0.119 £1,789 74
No CV event beneﬁt from exercise £237 0.263 £899 79 £221 0.131 £1,695 75
No mortality or CV event beneﬁt from exercise £219 0.211 £1,040 76 £219 0.119 £1,849 75
No difference in QoL beyond 1 year £190 0.051 £3,754 83 £215 0.009 £23,479 47
No difference in QoL beyond 1 year and no
mortality or CV event beneﬁt from exercise
£220 0.010 £21,200 49 £219 0.005 £48,017 41
Quality of life calculations
Using only EXITPAD EQ-5D values to inform QoL £191 0.270 £706 74 £215 0.128 £1,685 69
Using mean difference in absolute mean QoL £191 0.237 £805 78 £215 0.115 £1,874 73
Using only mapped SF-36 values to inform QoL £191 0.094 £2,028 64 £215 0.052 £4,117 62
Using only values from Savage et al., to inform
QoL
£190 0.364 £523 65 £215 0.154 £1,395 60
Costs
Decreased cost of supervised programmeb £147 0.265 £556 80 £174 0.133 £1,310 75
Increased cost of supervised programmeb £233 0.265 £880 79 £258 0.133 £1,941 74
Discount rates
Rate of 1.5% for QALYs and 3.5% for costs £190 0.304 £626 80 £215 0.145 £1,483 74
D ¼ difference between supervised and unsupervised exercise interventions; SE ¼ supervised exercise; CE ¼ cost effective;
CV ¼ cardiovascular; SA ¼ sensitivity analysis; QoL ¼ quality of life; EQ-5D ¼ EuroQol 5-Dimension questionnaire. a At a threshold of
£20, 00 per QALY gained. b Exlpored using upper and lower conﬁdence intervals of baseline
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health associated with exercise.5 Our study is the ﬁrst to
systematically identify QoL associated with exercise in pa-
tients with PAD and apply a validated mapping algorithm to
estimate preference-based values. It is also the ﬁrst cost-
utility analysis to account for the impact of exercise on CV
events and mortality. Sensitivity analysis showed that by
removing these assumptions, our results are similar to
those reported by van Asselt et al.,5 and SE would not be
considered cost-effective at a threshold of £20,000 per
QALY gained.
Our study has raised several important questions that
need to be addressed by future research. The optimum
duration and components of SE programmes remain un-
clear, with no RCTs directly comparing the efﬁcacy or cost
implications of different frequencies or duration of exercise
programmes. There is also a surprising lack of data regarding
compliance to each type of programme over time. Lastly,
people with IC may be reluctant to begin SE. There is a need
for future research to investigate people’s beliefs and per-
ceptions about exercise so as to better encourage uptake of
these programmes among people with PAD and educate
healthcare professionals about the information needs of
their patients.FUNDING
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